Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Young-Choon Moon"'
Autor:
Anuradha Bhattacharyya, Christopher R. Trotta, Jana Narasimhan, Kari J. Wiedinger, Wencheng Li, Kerstin A. Effenberger, Matthew G. Woll, Minakshi B. Jani, Nicole Risher, Shirley Yeh, Yaofeng Cheng, Nadiya Sydorenko, Young-Choon Moon, Gary M. Karp, Marla Weetall, Amal Dakka, Vijayalakshmi Gabbeta, Nikolai A. Naryshkin, Jason D. Graci, Thomas Tripodi, Amber Southwell, Michael Hayden, Joseph M. Colacino, Stuart W. Peltz
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Here the authors describe the discovery of a class of small molecule splicing modifiers which are orally bioavailable, cross the blood-brain barrier, and lower levels of huntingtin in a mouse model of Huntington’s disease (HD).
Externí odkaz:
https://doaj.org/article/7d4bfc4e0c074bdc9d52a1e84c8c63c4
Autor:
Ronald Kong, Jiyuan Ma, Seongwoo Hwang, Young‐Choon Moon, Ellen M. Welch, Marla Weetall, Joseph M. Colacino, Neil Almstead, John Babiak, Elizabeth Goodwin
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract Ataluren promotes ribosomal readthrough of premature termination codons in mRNA which result from nonsense mutations. In vitro studies were performed to characterize the metabolism and enzyme kinetics of ataluren and its interaction potentia
Externí odkaz:
https://doaj.org/article/eec39a36fe20492083ddc177954b3161
Autor:
Westley J Friesen, Briana Johnson, Jairo Sierra, Jin Zhuo, Priya Vazirani, Xiaojiao Xue, Yuki Tomizawa, Ramil Baiazitov, Christie Morrill, Hongyu Ren, Suresh Babu, Young-Choon Moon, Art Branstrom, Anna Mollin, Jean Hedrick, Josephine Sheedy, Gary Elfring, Marla Weetall, Joseph M Colacino, Ellen M Welch, Stuart W Peltz
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0206158 (2018)
Nonsense mutations, resulting in a premature stop codon in the open reading frame of mRNAs are responsible for thousands of inherited diseases. Readthrough of premature stop codons by small molecule drugs has emerged as a promising therapeutic approa
Externí odkaz:
https://doaj.org/article/dce988ac8f214e27afc02d4bfe8cf531
Autor:
Liangxian Cao, Marla Weetall, Jenelle Bombard, Hongyan Qi, Tamil Arasu, William Lennox, Jean Hedrick, Josephine Sheedy, Nicole Risher, Peter C Brooks, Panayiota Trifillis, Christopher Trotta, Young-Choon Moon, John Babiak, Neil G Almstead, Joseph M Colacino, Thomas W Davis, Stuart W Peltz
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0168366 (2016)
Current anti-VEGF (Vascular Endothelial Growth Factor A) therapies to treat various cancers indiscriminately block VEGF function in the patient resulting in the global loss of VEGF signaling which has been linked to dose-limiting toxicities as well a
Externí odkaz:
https://doaj.org/article/429e9fa300c64e3997b2fda5fbe6a256
Autor:
Stuart W. Peltz, Joseph M. Colacino, Art Branstrom, Neil G. Almstead, Allan Jacobson, Thomas W. Davis, John Babiak, Young-Choon Moon, Janet Petruska, Ronald Kong, William Lennox, Seongwoo Hwang, Tamil Arasu, Hongyan Qi, Shirley Yeh, Nicole Risher, Jean Hedrick, Josephine Sheedy, Joshua Du, Wencheng Li, Jason D. Graci, Charles Romfo, Bansri Furia, Min Jung Kim, Jiyuan Ma, Katherine Cintron, Christopher Trotta, Marla Weetall, Liangxian Cao
PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b38cf3c29f914ea98d3f3c7be961d2f
https://doi.org/10.1158/1535-7163.c.6539454.v1
https://doi.org/10.1158/1535-7163.c.6539454.v1
Autor:
Stuart W. Peltz, Joseph M. Colacino, Art Branstrom, Neil G. Almstead, Allan Jacobson, Thomas W. Davis, John Babiak, Young-Choon Moon, Janet Petruska, Ronald Kong, William Lennox, Seongwoo Hwang, Tamil Arasu, Hongyan Qi, Shirley Yeh, Nicole Risher, Jean Hedrick, Josephine Sheedy, Joshua Du, Wencheng Li, Jason D. Graci, Charles Romfo, Bansri Furia, Min Jung Kim, Jiyuan Ma, Katherine Cintron, Christopher Trotta, Marla Weetall, Liangxian Cao
Supplementary Figures S1-S7: Supplementary Figure S1 shows chemical Synthesis and biological characterization of PTC299. Supplementary Figure S2 shows generation and characterization of PTC299-resistant HT1080 cells. Supplementary Figure 3 shows that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ac4776ab8dbd1c4bd81dcd8bb2dab7
https://doi.org/10.1158/1535-7163.22509942
https://doi.org/10.1158/1535-7163.22509942
Autor:
Resham Bhattacharya, Thomas Davis, Melissa Dumble, Young-Choon Moon, Ramil Baiazitov, Nadiya Sydorenko, Liangxian Cao, Priyabrata Mukherjee, Soumyajit Banerjee Mustafi, Shailendra Kumar Dhar Dwivedi, Aleia Crim, Xunhao Xiong, Anindya Dey
Figure S1: Synthesis of PTC-028; Figure S2: Specificity of PTC-028 towards high BMI-1 expressing cells; Figure S3: PTC-028 induces caspase-dependent apoptosis; Figure S4: Pharmacokinetics of PTC-028 after a single oral dose of either 10 mg/kg or 20mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7067bb23f02dcfbe5b7d93fc900eb596
https://doi.org/10.1158/1535-7163.22505569
https://doi.org/10.1158/1535-7163.22505569
Autor:
Resham Bhattacharya, Thomas Davis, Melissa Dumble, Young-Choon Moon, Ramil Baiazitov, Nadiya Sydorenko, Liangxian Cao, Priyabrata Mukherjee, Soumyajit Banerjee Mustafi, Shailendra Kumar Dhar Dwivedi, Aleia Crim, Xunhao Xiong, Anindya Dey
BMI-1, also known as a stem cell factor, is frequently upregulated in several malignancies. Elevated expression of BMI-1 correlates with poor prognosis and is therefore considered a viable therapeutic target in a number of malignancies including ovar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6247e24dc7c55414166ca4c4497592ba
https://doi.org/10.1158/1535-7163.c.6538120.v1
https://doi.org/10.1158/1535-7163.c.6538120.v1
Autor:
Stuart W. Peltz, Joseph M. Colacino, Art Branstrom, Neil G. Almstead, Allan Jacobson, Thomas W. Davis, John Babiak, Young-Choon Moon, Janet Petruska, Ronald Kong, William Lennox, Seongwoo Hwang, Tamil Arasu, Hongyan Qi, Shirley Yeh, Nicole Risher, Jean Hedrick, Josephine Sheedy, Joshua Du, Wencheng Li, Jason D. Graci, Charles Romfo, Bansri Furia, Min Jung Kim, Jiyuan Ma, Katherine Cintron, Christopher Trotta, Marla Weetall, Liangxian Cao
contains the raw data from the Microarrays study in the PTC299-resistant HT1080 cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ffd21a73c725157d53ebd64ecdca72
https://doi.org/10.1158/1535-7163.22509948.v1
https://doi.org/10.1158/1535-7163.22509948.v1
Autor:
Hatem E. Sabaawy, Joseph Bertino, Robert S. DiPaola, Thomas W. Davis, Isaac Y. Kim, Mark N. Stein, John Kerrigan, Daniel Medina, Hua Zhong, Young-Choon Moon, Nadiya Sydorenko, Liangxian Cao, Daniel Jones, Michele Patrizii, Eric Huselid, Kathleen Flaherty, Stephani Davis, Shamila Yusuff, Monica Bartucci, Nitu Bansal
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1 regulates stem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::925153583244741b63d2ce956090ae1f
https://doi.org/10.1158/1078-0432.c.6527079.v1
https://doi.org/10.1158/1078-0432.c.6527079.v1